Factores asociados al desarrollo de efectos secundarios en pacientes con artritis reumatoide tratados con anti-factor de necrosis tumoral alfa

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Seminarios de la Fundación Española de Reumatología

• Publication date

  2013-07-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/J.SEMREU.2013.04.001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.

  2012cited by this paper
• Tumor Necrosis Factor Inhibitor Therapy and Cancer Risk in Chronic Immune-Mediated Diseases

  2012cited by this paper
• Use of a disease risk score to compare serious infections associated with anti–tumor necrosis factor therapy among high‐ versus lower‐risk rheumatoid arthritis patients

  2012cited by this paper
• Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.

  2012cited by this paper
• Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

  2011cited by this paper
• Initiation of rheumatoid arthritis treatments and the risk of serious infections.

  2010cited by this paper
• No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register

  2010cited by this paper
• High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study.

  2008cited by this paper
• Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

  2007cited by this paper
• Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

  2007cited by this paper
• All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

  2007cited by this paper
• The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

  2007cited by this paper
• Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

  2007cited by this paper
• Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

  2006cited by this paper
• Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

  2005cited by this paper
• The risk of lymphoma development in autoimmune diseases: a meta-analysis.

  2005cited by this paper
• Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

  2005cited by this paper
• Infections in patients with rheumatoid arthritis treated with biologic agents.

  2005cited by this paper
• Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis

  2003cited by this paper
• Extended Report

  year unknowncited by this paper

• No citing papers are available for this paper.